Acucela surges after $148m Japan IPO
This article was originally published in Scrip
The US ophthalmic disease venture Acucela has floated on the Mothers high-tech bourse of the Tokyo Stock Exchange, raising JPY15.15bn (around $148m) to progress its lead drug emixustat and other projects.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.